Text Size
18 studies found for:    "microbicide" AND "gel" | Open Studies | HIV

Modify this search | How to Use Search Results

Show Display Options
RSS Create an RSS feed from your search for:
"microbicide" AND "gel" | Open Studies | HIV
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Safety of Acidform Lubricant in HIV-Uninfected Women
Condition: HIV Infections
Interventions: Drug: Acidform Lubricant;   Drug: HEC gel
2 Recruiting Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection
Condition: HIV Prevention
Interventions: Drug: Tenofovir gel;   Drug: Universal placebo gel
3 Recruiting Microbicide Safety and Acceptability in Young Men
Conditions: High Risk MSM;   HIV Negative;   18-30 Years of Age
Interventions: Other: HEC Placebo Gel;   Drug: Tenofovir 1% Gel
4 Recruiting Tenofovir Gel in Pregnancy and Lactation
Condition: HIV Infections
Interventions: Drug: Tenofovir 1% gel;   Other: Placebo gel
5 Recruiting A Study to Compare Three Different Formulations of Tenofovir 1% Gel When Administered Rectally
Condition: HIV Prevention
Interventions: Drug: Rectal formulation (RF) of tenofovir 1% gel;   Drug: Vaginal formulations (original VF and reduced vaginal glycerin formulation RGVF) of tenofovir 1% gel;   Drug: Universal HEC Placebo Gel Formulation
6 Recruiting An Exploratory Rectal Safety Study of Three Tenofovir Gel Formulations
Condition: HIV Prevention
Interventions: Drug: Rectal formulation (RF) of tenofovir 1% gel;   Drug: Vaginal formulation (VF) of tenofovir 1% gel;   Drug: Reduced glycerin vaginal formulation (RGVF) of tenofovir 1% gel;   Radiation: Radiolabeling of study drugs and semen
7 Recruiting Implementation Effectiveness and Safety of Tenofovir Gel Provision Through Family Planning Services
Condition: HIV
Intervention: Drug: 1% tenofovir gel
8 Not yet recruiting Tenofovir Levels Following Local Application of Tenofovir Reduced-Glycerin 1% Gel
Condition: HIV Prevention
Interventions: Drug: Once Daily Application of TFV RG 1% Gel;   Drug: Once Daily Application of TFV RG 1% gel - Rectal;   Drug: Once Daily Application of TFV RG 1% Gel - Vaginal
9 Unknown † An Imaging Trial of the Distribution of Topical Gel in the Human Vagina: Assessment of Bare Spots
Condition: HIV Infections
Intervention: Drug: HEC placebo gel
10 Not yet recruiting Biomarkers of Protocol Compliance and Product Adherence
Condition: HIV Prevention
Intervention: Other: HEC placebo gel applicators
11 Recruiting Assessing the Safety of Dapivirine Gel and Film Formulations
Condition: HIV Infections
Interventions: Drug: Dapivirine Vaginal Film;   Drug: Dapivirine Vaginal Gel
12 Not yet recruiting Evaluating the Safety of Tenofovir Vaginal Gel in HIV-Uninfected Pregnant Women
Condition: HIV Infections
Interventions: Drug: 1% tenofovir gel;   Drug: Placebo gel
13 Not yet recruiting Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel
Condition: HIV
Interventions: Drug: Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet);   Drug: Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel);   Drug: Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel)
14 Not yet recruiting In Vivo Drug Interaction Pharmacokinetic Study of Tenofovir 1% Gel and Three Commonly Used Vaginal Products
Condition: HIV Prevention
Interventions: Drug: Tenofovir 1% gel;   Drug: Vaginal product
15 Recruiting Contraception and Menstrual Cycle Effect on Pharmacokinetics, Pharmacodynamics and Safety in Tenofovir Vaginal Gel Use
Condition: HIV Prevention
Interventions: Drug: Tenofovir 1% vaginal gel;   Drug: Depo-medroxyprogesterone acetate (DMPA);   Drug: Oral contraceptive: LNG 150 mcg and EE 30 mcg
16 Unknown † A Multicenter Study to Assess the Tolerability of Once Daily Lopinavir/Ritonavir (LPV/r) Liquid Versus Capsules
Condition: HIV Infection
Intervention: Drug: Different formulations of once-daily lopinavir/ritonavir
17 Recruiting KONCERT A Kaletra ONCE Daily Randomised Trial of the Pharmacokinetics, Safety and Efficacy of Twice-daily Versus Once-daily Lopinavir/Ritonavir Tablets Dosed by Weight as Part of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-1 (HIV-1) Infected Children (PENTA 18)
Condition: Antiretroviral Therapy in HIV-1 Infected Children
Interventions: Drug: Kaletra dosed once daily;   Drug: kaletra dosed twice daily
18 Unknown † Dosing, Safety and Pharmacokinetic Profile of Rifabutin in Children Receiving Concomitant Treatment With Kaletra
Conditions: Children With Confirmed HIV Infection;   Receiving ART Regimen Containing 2 NRTIs + LPV/RTV at Standard Dose;   Successfully Completed TB Treatment in the Past 2 to 6 Weeks of Enrollment
Intervention: Drug: Mycobutin
To Top

† Indicates status has not been verified in more than two years